| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/19/2006 | EP1227820B1 Oligosaccharide aldonic acids and their topical use |
| 04/19/2006 | EP1210112B1 Vaccine against hbv and hpv |
| 04/19/2006 | EP1196167B1 Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions |
| 04/19/2006 | EP1143806B1 Method for increasing pet activity |
| 04/19/2006 | EP1107772B1 Composition with bacillus coagulans and use thereof |
| 04/19/2006 | EP1044197B1 Piperidinyl-substituted pyridylalkane, alkene and alkyne carboxamides as cytostatic agents and immunosuppressants |
| 04/19/2006 | EP1041987B1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone |
| 04/19/2006 | EP0912608B1 Choline binding proteins for anti-pneumococcal vaccines |
| 04/19/2006 | CN1761666A Polyhydroxylated pyrrolizidine |
| 04/19/2006 | CN1761487A Dispersible formulation of an anti-inflammatory agent |
| 04/19/2006 | CN1761486A Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 04/19/2006 | CN1761474A Actacid composition |
| 04/19/2006 | CN1761471A Combined use of ribavirin and interferon beta in demyelinating diseases |
| 04/19/2006 | CN1761460A Antiflatulents in combination with histamine H1-receptor antagonists for treating gastrointestinal disorders |
| 04/19/2006 | CN1761450A Skin preparation for external use characterized by containing sugar derivative of a,a-trehalose |
| 04/19/2006 | CN1759887A Mucous membrane absorption ingestion type medicinal composition for drawing out interferon, and preparation |
| 04/19/2006 | CN1252071C Xanthine Phosphodiesterase V inhibitors |
| 04/19/2006 | CN1252068C Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 |
| 04/19/2006 | CN1251707C Application of Engally nut oil in the preparation of medicine for treating arthritis |
| 04/19/2006 | CN1251687C Medicinal composition for treationg virus infention of rlavivirus family, set group and packaged products |
| 04/19/2006 | CN1251676C Phenyl xanthine derivative |
| 04/18/2006 | US7030242 Selective inhibition of aggrecanase in osteoarthritis treatment |
| 04/18/2006 | US7030162 Storage stabilized dosage |
| 04/18/2006 | US7030157 Hormone replacment therapy; anticancer agent; sexual disorders |
| 04/18/2006 | US7030149 Combination of brimonidine timolol for topical ophthalmic use |
| 04/18/2006 | US7030147 Synergistic mixture; antiproliferative agents; side effect reduction |
| 04/18/2006 | US7030132 An inhibitor of breast cancer resistance protein (BCRP) is orally administered concomitantly with a pharmaceutical compound. |
| 04/18/2006 | US7030131 such as N-[4-(4-amino-1H-imidazol[4,5-c]quinolin-1-yl)butyl]-5-(dimethylamino)-naphthalenesulfonamide; for induction of biosynthesis of cytokines; immunomodulators; antineoplastic agents |
| 04/18/2006 | US7030129 Method of reducing and treating UVB-induced immunosuppression |
| 04/18/2006 | US7030126 Use of polyamine analogs for amyotrophic lateral sclerosis |
| 04/18/2006 | US7030112 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 04/18/2006 | US7030108 Administering to patient effective amount of neurotransmission modulating composition comprising 5HT antagonist and/or alpha 2 antagonist |
| 04/18/2006 | US7030106 Ezetimibe formulation with lactose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate and microcrystalline cellulose |
| 04/18/2006 | US7030103 Such as ((benzylsulfonylamino)methyl)-phosphonic acid mono-(4-nitrophenyl)ester sodium salt; for treating bacterial antibiotic resistance |
| 04/18/2006 | US7030100 Analgesic inhibitor of isoforms of cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (PKGI alpha); drug screening |
| 04/18/2006 | US7030094 Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21 |
| 04/18/2006 | US7030089 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 04/18/2006 | US7030086 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 04/18/2006 | US7029914 DNA encoding SNORF36 receptors |
| 04/18/2006 | US7029898 Comprises chimeric polypeptide with hydrolase and mitogen activated protein kinase activity for diagnosis and treatment of cell proliferation and differentiation disorders |
| 04/18/2006 | US7029894 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 04/18/2006 | US7029869 Feeding assay for identifying nematicidal compounds |
| 04/18/2006 | US7029849 Kit for use in the diagnosis of hypertension; obtain sample, determine pattern of alleles, detect preferential gene expression, preferential gene expression indicates hypertension |
| 04/18/2006 | US7029755 Polyurethane-urea-silane copolymer for use as coatings that are elastic when dry, lubricious when wet, and resist wet abrasion; for coating rubber, medical devices (catheters, shunts) |
| 04/18/2006 | US7029710 For inhibiting amyloid formation, deposition, accumulation, or persistence, or amyloid protein-amyloid protein interactions, amyloid-proteoglycan interactions, amyloid-PG/GAG interactions and/or amyloid-glycosaminoglycan interactions |
| 04/18/2006 | US7029707 Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 04/18/2006 | US7029706 Composition for the treatment of cutaneous mycosis |
| 04/18/2006 | US7029703 Composition for promoting healthy bone structure |
| 04/18/2006 | US7029701 Composition for the treatment and prevention of ischemic events |
| 04/18/2006 | US7029674 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 04/18/2006 | US7029658 Delivery of antidepressants through an inhalation route |
| 04/18/2006 | US7029653 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
| 04/13/2006 | WO2006039256A1 Use of gpr103 agonists for modulating feeding behaviour |
| 04/13/2006 | WO2006038729A1 Mutated amyloid protein |
| 04/13/2006 | WO2006037482A2 Compositions and methods for treating cognitive disorders |
| 04/13/2006 | WO2005116032A3 Reverse-turn mimetics and method relating thereto |
| 04/13/2006 | WO2005097146A3 Dairy components effective for fat loss |
| 04/13/2006 | WO2005094798A3 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists |
| 04/13/2006 | WO2005082329A3 Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| 04/13/2006 | WO2005077411A3 Composition and method for the treatment of carcinoma |
| 04/13/2006 | WO2005074983A3 Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| 04/13/2006 | WO2005028504A3 Regulation of tissue mineralization and phosphate met abolism by asarm peptides |
| 04/13/2006 | WO2004032837A3 The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine |
| 04/13/2006 | US20060079563 Cyclic protein tyrosine kinase inhibitors |
| 04/13/2006 | US20060079545 Palonosetron for the treatment of chemotherapy induced emeses |
| 04/13/2006 | US20060079539 Synergistic combination |
| 04/13/2006 | US20060079518 Such as (S)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(2-methoxy-ethyl)-piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one bis hydrochloride; anticancer agents; antiproliferative agents |
| 04/13/2006 | US20060079488 Methods of treating and preventing bone loss |
| 04/13/2006 | US20060079484 Antithrombotic effect |
| 04/13/2006 | US20060079480 Novel antifolate combination therapies |
| 04/13/2006 | US20060079470 Combined dna vaccine and biological modifiers for cancer therapy |
| 04/13/2006 | US20060079464 Peritoneal dialysate containing taurine |
| 04/13/2006 | US20060079458 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 04/13/2006 | US20060079452 Administering anakinra |
| 04/13/2006 | US20060078956 Methods to identify compounds that modulate rage |
| 04/13/2006 | US20060078940 21132, a human G-protein coupled receptor family member and uses therefor |
| 04/13/2006 | US20060078918 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator |
| 04/13/2006 | US20060078901 Listeria monocytogenes genome, polypeptides and uses |
| 04/13/2006 | US20060078629 Nutritional compositions and use thereof |
| 04/13/2006 | US20060078582 Use of compositions for treating rosacea |
| 04/13/2006 | US20060078575 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 04/13/2006 | US20060078545 Neural progenitor cell populations |
| 04/13/2006 | DE10394216T5 Hepatoprotektive pharmazeutische Zusammensetzung umfassend eine Mischung aus Coumarinlignoiden und Verfahren zur Herstellung derselben Hepatoprotective pharmaceutical composition comprising a mixture of coumarinolignoids and methods for making the same |
| 04/13/2006 | DE10320633B4 Verfahren zur Identifizierung einer möglichen Modifikation von mindestens einem biologischen Parameter unter Verwendung von lebenden Zellen, die einem Reiz ausgesetzt wurden, und lebenden Zellen, die nicht diesem Reiz ausgesetzt wurden A method of identifying a possible modification of at least one biological parameter using living cells that were exposed to a stimulus, and living cells that were not exposed to this stimulus |
| 04/13/2006 | CA2583431A1 Variant amyloid protein |
| 04/13/2006 | CA2581282A1 Solid pharmaceutical preparation |
| 04/12/2006 | EP1645634A2 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/12/2006 | EP1645285A2 Therapeutical use of anti-mag antibody for the treatment of ischemic stroke |
| 04/12/2006 | EP1645278A2 Use of aliphatic polyamines for reducing oxalate |
| 04/12/2006 | EP1645273A2 Novel use of (R)-(-)-2-(5-(-flourophenyl)-3-pyridylmethylaminoethyl|-chromane and its physiologically acceptable salts |
| 04/12/2006 | EP1645271A1 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| 04/12/2006 | EP1644043A1 Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility |
| 04/12/2006 | EP1644042A1 A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| 04/12/2006 | EP1644041A1 A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| 04/12/2006 | EP1644040A1 Use of combinations of reverse transcriptase inhibitors and virus coded dna polymerase inhibitors |
| 04/12/2006 | EP1644033A2 Use of inhibitors of enzymes with aminopeptidase n and/or dipeptidylpeptidase iv activity and pharmaceutical preparations of said inhibitors for the treatment and prevention of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts |
| 04/12/2006 | EP1644024A2 Antimicrobial flush solutions |
| 04/12/2006 | EP1644010A2 Colloidal silver composition having antimicrobial properties |
| 04/12/2006 | EP1644000A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 04/12/2006 | EP1643999A1 Pyridoxamine for the treatment of diabetic kidney disease |